Posters

Analysis of AutonoMe/Clareon injector system using an intraocular endoscopic camera

Poster Details

First Author: G.Auffarth GERMANY

Co Author(s):    L. Zhang   H. Son   T. Yildirim   P. Merz           

Abstract Details

Purpose:

To evaluate the delivery of the new Clareon intraocular lens by the automated AutonoMe injector into the anterior chamber and capsular bag of human autopsy eyes and clinical patients.

Setting:

The David J Apple International Laboratory for Ocular Pathology, Dept. of Ophthalmology, University of Heidelberg

Methods:

In the laboratory part of the study, the human autopsy eyes were used and the incisions were made at 12 o´clock position of the cornea with a 2.5 mm incision. On the opposite side at 6 o´clock, a similar incision was performed and an intraocular endoscope, Ophthalmic Endoscopic System (Beaver-Visitec), was introduced. The analyses looked at formation of the leading haptic and the trauma of the delivery into the capsular bag. In the clinical situation, after incisions were made at 6 o´clock and 9 o´clock positions, the endoscope was introduced and the implantation recorded.

Results:

In most of the cases, the leading haptic came out in a question-mark fashion sliding directly under the capsulorhexis into the capsular bag. In individual cases, the haptic came out straight that could be maneuvered without any problem into the capsular bag. The second haptic then could be placed under the capsulorhexis into the capsular bag using the injector.

Conclusions:

The new AutonoMe system for delivery of the Clareon lens is a very good system to implant the IOL with minimal invasive forces and minimal invasive trauma, with very high reproducibility in terms of delivery of the first haptic which could be visualized very well with intraocular endoscope.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a competing company, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a competing company, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives non-monetary benefits from a competing company., receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented., receives consulting fees, retainer, or contract payments from a competing company